Neuroscience Section, Department of Medicine, Surgery and Dentistry, Center for Neurodegenerative Diseases (CEMAND), University of Salerno, Fisciano, Italy.
AOU S. Giovanni di Dio e Ruggi D'Aragona, Neurology Unit, Salerno, Italy.
Brain Behav. 2021 Oct;11(10):e2344. doi: 10.1002/brb3.2344. Epub 2021 Sep 7.
Depression is one of the most common neuropsychiatric symptoms in progressive supranuclear palsy (PSP). Yet, few studies have examined the ability of available instruments to detect depressive symptoms in PSP. Aims of the present study were to (I) report psychometric properties of the Beck Depression Inventory Second Edition (BDI-II) in PSP, (II) establish the BDI-II cut-off indicating the presence of depression in PSP and (III) describe clinical correlates as well as correlation with quality of life of depressive symptoms in PSP.
DESIGN, SETTING AND PARTICIPANTS: At the Center for Neurodegenerative Diseases of the University of Salerno, Italy, the BDI-II was validated in 62 PSP patients diagnosed according to the Movement Disorder Society criteria. Patients underwent a clinical interview, a motor evaluation, extensive cognitive and behavioral testing.
The mean BDI-II total score was 15.92 ± 10.31. The internal consistency was high (Cronbach's alpha = 0.868); corrected item-total correlation was >0.40 for the majority of items. The significant and moderate correlation of the BDI-II with other tools evaluating depressive symptoms indicated adequate convergent validity of the scale. The satisfactory cut-off to identify patients with clinically significant depression was >14.5. We also showed a correlation between higher scores on BDI-II and lower quality of life, irrespective of motor and cognitive burden.
In conclusion, the BDI-II is a reliable and valid tool for the assessment of depression symptoms in PSP. Such data are useful to standardize studies of depression in PSP and to quantify the effectiveness of any interventions on this disabling symptom.
抑郁是进行性核上性麻痹（PSP）中最常见的神经精神症状之一。然而，很少有研究检查现有工具检测 PSP 中抑郁症状的能力。本研究的目的是：（I）报告贝克抑郁量表第二版（BDI-II）在 PSP 中的心理测量特性，（II）确定 BDI-II 临界值，以指示 PSP 中存在抑郁，（III）描述 PSP 中抑郁症状的临床相关性以及与生活质量的相关性。
设计、地点和参与者：在意大利萨莱诺大学神经退行性疾病中心，根据运动障碍协会标准，对 62 名 PSP 患者进行了 BDI-II 验证。患者接受了临床访谈、运动评估、广泛的认知和行为测试。
BDI-II 总分的平均值为 15.92±10.31。内部一致性很高（Cronbach's alpha=0.868）；大多数项目的校正项目-总分相关性>0.40。BDI-II 与评估抑郁症状的其他工具的显著和中度相关性表明该量表具有足够的聚合效度。确定有临床显著抑郁的患者的理想临界值为>14.5。我们还表明，BDI-II 得分越高，生活质量越低，无论运动和认知负担如何。
总之，BDI-II 是评估 PSP 中抑郁症状的可靠有效工具。这些数据有助于 PSP 中抑郁研究的标准化，并量化任何干预措施对这种致残症状的有效性。
